The metabolic syndrome

Lancet

Volumn 365, Issue 9468, 2005, Pages 1415-1428

  Eckel, Robert H ^a   Grundy, Scott M ^b   Zimmet, Paul Z ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ADIPONECTIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NATEGLINIDE; NICOTINIC ACID; REPAGLINIDE; SULFONYLUREA; THIAZIDE DIURETIC AGENT;

ATHEROGENIC DIET; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; COMORBIDITY; CONFERENCE PAPER; DIABETES MELLITUS; DYSLIPIDEMIA; FATTY LIVER; GLUCOSE INTOLERANCE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMOBILIZATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; WAIST CIRCUMFERENCE;

EID: 17144380822     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)66378-7     Document Type: Conference Paper

References (164)

1. AJ Cameron, JE Shaw, PZ Zimmet The metabolic syndrome: prevalence in worldwide populations Endocrinol Metab Clin North Am 33 2004 351 375
2. E Kylin Studien. Hypertonie-Hyperglykamie-Hyperurikamiesyndrome Zentralblatt fur innere Medizin 44 1923
3. J Vague La differenciation sexuelle, facteur determinant des formes de l'obesite Presse Med 30 1947 339 340
4. P Zimmet, KG Alberti, J Shaw Global and societal implications of the diabetes epidemic Nature 414 2001 782 787
5. SM Grundy, B Hansen, SC Smith Jr, JI Cleeman, RA Kahn Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management Circulation 109 2004 551 556
6. GM Reaven Banting lecture 1988. Role of insulin resistance in human disease Diabetes 37 1988 1595 1607
7. RA DeFronzo, E Ferrannini Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease Diabetes Care 14 1991 173 194
8. NM Kaplan The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension Arch Intern Med 149 1989 1514 1520
9. B Isomaa, P Almgren, T Tuomi Cardiovascular morbidity and mortality associated with the metabolic syndrome Diabetes Care 24 2001 683 689
10. HM Lakka, DE Laaksonen, TA Lakka The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men JAMA 288 2002 2709 2716
11. I Lemieux, A Pascot, C Couillard Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 102 2000 179 184
12. GM Reaven Insulin resistance, cardiovascular disease, and the metabolic syndrome: how well do the emperor's clothes fit? Diabetes Care 27 2004 1011 1012
13. KG Alberti, PZ Zimmet Definition, diagnosis and classification of diabetes mellitus and its complications. Part1 diagnosis and classification of diabetes mellitus provisional report of a WHO consultation Diabet Med 15 1998 539 553
14. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
15. B Balkau, MA Charles Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR) Diabet Med 16 1999 442 443
16. DR Matthews, JP Hosker, AS Rudenski, BA Naylor, DF Treacher, RC Turner Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
17. D Einhorn, GM Reaven, RH Cobin American College of Endocrinology position statement on the insulin resistance syndrome Endocr Pract 9 2002 236 252
18. RH Eckel Obesity: mechanisms and clinical management 2003 Lippincott Williams & Wilkins Philadelphia (PA)
19. World Health Organisation, Western Pacific Region The Asia-Pacific Perspective. Redefining Obesity and its Treatment 2000 WHO/IASO/IOTF
20. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies Lancet 363 2004 157 163
21. ES Ford, WH Giles, WH Dietz Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey JAMA 287 2002 356 359
22. F Azizi, P Salehi, A Etemadi, S Zahedi-Asl Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study Diabetes Res Clin Pract 61 2003 29 37
23. R Sinha, G Fisch, B Teague Prevalence of impaired glucose tolerance among children and adolescents with marked obesity N Engl J Med 346 2002 802 810
24. JN Wei, FC Sung, CC Lin, RS Lin, CC Chiang, LM Chuang National surveillance for type 2 diabetes mellitus in Taiwanese children JAMA 290 2003 1345 1350
25. RY Sung, PC Tong, CW Yu High prevalence of insulin resistance and metabolic syndrome in overweight/obese preadolescent Hong Kong Chinese children aged 9-12 years Diabetes Care 26 2003 250 251
26. R Weiss, J Dziura, TS Burgert Obesity and the metabolic syndrome in children and adolescents N Engl J Med 350 2004 2362 2374
27. S Cook, M Weitzman, P Auinger, M Nguyen, WH Dietz Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994 Arch Pediatr Adolesc Med 157 2003 821 827
28. CJ Girman, T Rhodes, M Mercuri The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Am J Cardiol 93 2004 136 141
29. S Malik, ND Wong, SS Franklin Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults Circulation 110 2004 1245 1250
30. RL Hanson, G Imperatore, PH Bennett, WC Knowler Components of the "metabolic syndrome" and incidence of type 2 diabetes Diabetes 51 2002 3120 3127
31. DE Laaksonen, HM Lakka, LK Niskanen, GA Kaplan, JT Salonen, TA Lakka Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study Am J Epidemiol 156 2002 1070 1077
32. G Hu, Q Qiao, J Tuomilehto, B Balkau, K Borch-Johnsen, K Pyorala Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women Arch Intern Med 164 2004 1066 1076
33. E Bonora, G Targher, G Formentini The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study Diabet Med 21 2004 52 58
34. JK Ninomiya, G L'Italien, MH Criqui, JL Whyte, A Gamst, RS Chen Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutrition examination survey Circulation 109 2004 42 46
35. S Yusuf, S Hawken, S Ounpuu Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 2004 937 952
36. MP Stern, K Williams, C Gonzalez-Villalpando, KJ Hunt, SM Haffner Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 27 2004 2676 2681
37. RH Eckel Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases N Engl J Med 320 1989 1060 1068
38. MD Jensen, M Caruso, V Heiling, JM Miles Insulin regulation of lipolysis in nondiabetic and IDDM subjects Diabetes 38 1989 1595 1601
39. YB Kim, GI Shulman, BB Kahn Fatty acid infusion selectively impairs insulin action on Akt1 and protein kinase C lambda/zeta but not on glycogen synthase kinase-3 J Biol Chem 277 2002 32915 32922
40. JA Chavez, TA Knotts, LP Wang A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids J Biol Chem 278 2003 10297 10303
41. VT Samuel, ZX Liu, X Qu Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease J Biol Chem 279 2004 32345 32353
42. G Boden, GI Shulman Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction Eur J Clin Invest 32 suppl 3 2002 14 23
43. I Shimomura, Y Bashmakov, S Ikemoto, JD Horton, MS Brown, JL Goldstein Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes Proc Natl Acad Sci USA 96 1999 13656 13661
44. DE Kelley, J He, EV Menshikova, VB Ritov Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes Diabetes 51 2002 2944 2950
45. KF Petersen, S Dufour, D Befroy, R Garcia, GI Shulman Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes N Engl J Med 350 2004 664 671
46. KF Petersen, D Befroy, S Dufour Mitochondrial dysfunction in the elderly: possible role in insulin resistance Science 300 2003 1140 1142
47. U Ozcan, Q Cao, E Yilmaz Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes Science 306 2004 457 461
48. N Ruderman, D Chisholm, X Pi-Sunyer, S Schneider The metabolically obese, normal-weight individual revisited Diabetes 47 1998 699 713
49. S Lee, I Janssen, R Ross Interindividual variation in abdominal subcutaneous and visceral adipose tissue: influence of measurement site J Appl Physiol 97 2004 948 954
50. H Aubert, C Frere, MF Aillaud, PE Morange, I Juhan-Vague, MC Alessi Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome J Thromb Haemost 1 2003 791 797
51. M Bajaj, MA Banerji Type 2 diabetes in South Asians: a pathophysiologic focus on the Asian-Indian epidemic Curr Diab Rep 4 2004 213 218
52. S Tanaka, C Horimai, F Katsukawa Ethnic differences in abdominal visceral fat accumulation between Japanese, African-Americans, and Caucasians: a meta-analysis Acta Diabetol 40 suppl 1 2003 S302 S304
53. Z Guo, DD Hensrud, CM Johnson, MD Jensen Regional postprandial fatty acid metabolism in different obesity phenotypes Diabetes 48 1999 1586 1592
54. A Garg, A Misra Lipodystrophies: rare disorders causing metabolic syndrome Endocrinol Metab Clin North Am 33 2004 305 331
55. RA Hegele Monogenic forms of insulin resistance: apertures that expose the common metabolic syndrome Trends Endocrinol Metab 14 2003 371 377
56. J Dallongeville, N Helbecque, D Cottel, P Amouyel, A Meirhaeghe The Gly16 - >Arg16 and Gln27 - >Glu27 polymorphisms of beta2-adrenergic receptor are associated with metabolic syndrome in men J Clin Endocrinol Metab 88 2003 4862 4866
57. F Fumeron, R Aubert, A Siddiq Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3-year period: the epidemiologic data on the insulin resistance syndrome prospective study Diabetes 53 2004 1150 1157
58. GF Lewis, KD Uffelman, LW Szeto, B Weller, G Steiner Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans J Clin Invest 95 1995 158 166
59. GF Lewis, G Steiner Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state Diabetes Care 19 1996 390 393
60. C Taghibiglou, F Rashid-Kolvear, SC Van Iderstine Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance J Biol Chem 277 2002 793 803
61. F Foufelle, P Ferre New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c Biochem J 366 2002 377 391
62. RH Eckel, TJ Yost, DR Jensen Alterations in lipoprotein lipase in insulin resistance Int J Obes Relat Metab Disord 19 suppl 1 1995 S16 S21
63. T Murakami, S Michelagnoli, R Longhi Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma Arterioscler Thromb Vasc Biol 15 1995 1819 1828
64. EA Brinton, S Eisenberg, JL Breslow Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein- cholesterol levels with or without hypertriglyceridemia J Clin Invest 87 1991 536 544
65. J de Graaf, JC Hendriks, PN Demacker, AF Stalenhoef Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment Arterioscler Thromb 13 1993 712 719
66. E Manzato, S Zambon, A Zambon, A Cortella, G Sartore, G Crepaldi Levels and physicochemical properties of lipoprotein subclasses in moderate hypertriglyceridemia Clin Chim Acta 219 1993 57 65
67. M Halle, A Berg, MW Baumstark, D Konig, M Huonker, J Keul Influence of mild to moderately elevated triglycerides on low density lipoprotein subfraction concentration and composition in healthy men with low high density lipoprotein cholesterol levels Atherosclerosis 143 1999 185 192
68. PO Kwiterovich Jr Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity Am J Cardiol 90 2002 30i 47i
69. CJ Packard LDL subfractions and atherogenicity: an hypothesis from the University of Glasgow Curr Med Res Opin 13 1996 379 390
70. RM Krauss Dense low density lipoproteins and coronary artery disease Am J Cardiol 75 1995 53B 57B
71. AT Lada, LL Rudel Associations of low density lipoprotein particle composition with atherogenicity Curr Opin Lipidol 15 2004 19 24
72. A Zambon, JE Hokanson, BG Brown, JD Brunzell Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density Circulation 99 1999 1959 1964
73. FM Sacks, H Campos Clinical review 163: Cardiovascular endocrinology: Low-density lipoprotein size and cardiovascular disease: a reappraisal J Clin Endocrinol Metab 88 2003 4525 4532
74. Y Lee, H Hirose, M Ohneda, JH Johnson, JD McGarry, RH Unger Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships Proc Natl Acad Sci USA 91 1994 10878 10882
75. GC Yaney, BE Corkey Fatty acid metabolism and insulin secretion in pancreatic beta cells Diabetologia 46 2003 1297 1312
76. A Boucher, D Lu, SC Burgess Biochemical mechanism of lipid-induced impairment of glucose-stimulated insulin secretion and reversal with a malate analogue J Biol Chem 279 2004 27263 27271
77. JW Joseph, V Koshkin, MC Saleh Free fatty acid induced beta cell defects are dependent on uncoupling protein 2 expression J Biol Chem 279 2004 15049 15056
78. JC Bruning, MD Michael, JN Winnay A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance Mol Cell 2 1998 559 569
79. RN Kulkarni, JC Bruning, JN Winnay, C Postic, MA Magnuson, CR Kahn Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes Cell 96 1999 329 339
80. E Ferrannini, G Buzzigoli, R Bonadonna Insulin resistance in essential hypertension N Engl J Med 17 1987 350 357
81. HO Steinberg, G Brechtel, A Johnson, N Fineberg, AD Baron Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release J Clin Invest 94 1994 1172 1179
82. RA DeFronzo, CR Cooke, R Andres, GR Faloona, PJ Davis The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man J Clin Invest 55 1975 845 855
83. A Barbato, FP Cappuccio, EJ Folkerd Metabolic syndrome and renal sodium handling in three ethnic groups living in England Diabetologia 47 2004 40 46
84. JE Tooke, MM Hannemann Adverse endothelial function and the insulin resistance syndrome J Intern Med 247 2000 425 431
85. S Kuroda, T Uzu, T Fujii Role of insulin resistance in the genesis of sodium sensitivity in essential hypertension J Hum Hypertens 13 1999 257 262
86. D Tripathy, P Mohanty, S Dhindsa Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects Diabetes 52 2003 2882 2887
87. EA Anderson, RP Hoffman, TW Balon, CA Sinkey, AL Mark Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans J Clin Invest 87 1991 2246 2252
88. BM Egan Insulin resistance and the sympathetic nervous system Curr Hypertens Rep 5 2003 247 254
89. AJ Hanley, AJ Karter, A Festa Factor analysis of metabolic syndrome using directly measured insulin sensitivity: The Insulin Resistance Atherosclerosis Study Diabetes 51 2002 2642 2647
90. J Choudhury, AJ Sanyal Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease Clin Liver Dis 8 2004 575 594 ix
91. BA Neuschwander-Tetri, SH Caldwell Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference Hepatology 37 2003 1202 1219
92. B Eliasson, S Attvall, MR Taskinen, U Smith The insulin resistance syndrome in smokers is related to smoking habits Arterioscler Thromb 14 1994 1946 1950
93. TA Lakka, DE Laaksonen, HM Lakka Sedentary lifestyle, poor cardiorespiratory fitness, and the metabolic syndrome Med Sci Sports Exerc 35 2003 1279 1286
94. A Onat, G Hergenc, V Sansoy Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders Atherosclerosis 168 2003 81 89
95. J Medina, LI Fernandez-Salazar, L Garcia-Buey, R Moreno-Otero Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis Diabetes Care 27 2004 2057 2066
96. F Facchini, YD Chen, CB Hollenbeck, GM Reaven Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration JAMA 266 1991 3008 3011
97. K Rowley, K O'Dea, JD Best Association of albuminuria and the metabolic syndrome Curr Diab Rep 3 2003 80 86
98. J Sutherland, B McKinnley, RH Eckel The Metabolic Syndrome and Inflammation Metabolic Syndr Rel Disord 2 2004 82 104
99. JM Fernandez-Real, W Ricart Insulin resistance and chronic cardiovascular inflammatory syndrome Endocr Rev 24 2003 278 301
100. P Trayhurn, IS Wood Adipokines: inflammation and the pleiotropic role of white adipose tissue Br J Nutr 92 2004 347 355
101. SP Weisberg, D McCann, M Desai, M Rosenbaum, RL Leibel, AW Ferrante Jr Obesity is associated with macrophage accumulation in adipose tissue J Clin Invest 112 2003 1796 1808
102. H Xu, GT Barnes, Q Yang Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance J Clin Invest 112 2003 1821 1830
103. MJ LaMonte, JL Durstine, FG Yanowitz Cardiorespiratory fitness and C-reactive protein among a tri-ethnic sample of women Circulation 106 2002 403 406
104. JC Chambers, S Eda, P Bassett C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites Circulation 104 2001 145 150
105. AR Nawrocki, PE Scherer The delicate balance between fat and muscle: adipokines in metabolic disease and musculoskeletal inflammation Curr Opin Pharmacol 4 2004 281 289
106. TP Combs, AH Berg, S Obici, PE Scherer, L Rossetti Endogenous glucose production is inhibited by the adipose-derived protein Acrp30 J Clin Invest 108 2001 1875 1881
107. T Yamauchi, K Hara, N Kubota Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and anti-atherogenic adipokine Curr Drug Targets Immune Endocr Metabol Disord 3 2003 243 254
108. Y Matsuzawa, T Funahashi, S Kihara, I Shimomura Adiponectin and metabolic syndrome Arterioscler Thromb Vasc Biol 24 2004 29 33
109. T Pischon, CJ Girman, GS Hotamisligil, N Rifai, FB Hu, EB Rimm Plasma adiponectin levels and risk of myocardial infarction in men JAMA 291 2004 1730 1737
110. DM Maahs, LG Ogden, GL Kinney Low plasma adiponectin levels predict progression of coronary artery calcification Circulation 111 2005 747 753
111. AJ Hanley, LE Wagenknecht, RB D'Agostino Jr, B Zinman, SM Haffner Identification of subjects with insulin resistance and beta-cell dysfunction using alternative definitions of the metabolic syndrome Diabetes 52 2003 2740 2747
112. BJ Shen, JF Todaro, R Niaura Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X Am J Epidemiol 157 2003 701 711
113. RH Unger Lipid overload and overflow: metabolic trauma and the metabolic syndrome Trends Endocrinol Metab 14 2003 398 403
114. T Kakuma, Y Lee, M Higa Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets Proc Natl Acad Sci USA 97 2000 8536 8541
115. Y Minokoshi, BB Kahn Role of AMP-activated protein kinase in leptin-induced fatty acid oxidation in muscle Biochem Soc Trans 31 2003 196 201
116. JA Cases, I Gabriely, XH Ma Physiological increase in plasma leptin markedly inhibits insulin secretion in vivo Diabetes 50 2001 348 352
117. J Seufert Leptin effects on pancreatic beta-cell gene expression and function Diabetes 53 suppl 1 2004 S152 S158
118. KJ Hunt, RG Resendez, K Williams, SM Haffner, MP Stern National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study Circulation 110 2004 1251 1257
119. PW Wilson Estimating cardiovascular disease risk and the metabolic syndrome: a Framingham view Endocrinol Metab Clin North Am 33 2004 467 481
120. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3221
121. RM Conroy, K Pyorala, AP Fitzgerald Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project Eur Heart J 24 2003 987 1003
122. SM Grundy, HB Brewer Jr, JI Cleeman, SC Smith Jr, C Lenfant Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition Circulation 109 2004 433 438
123. B Lamarche, A Tchernof, P Mauriege Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease JAMA 279 1998 1955 1961
124. G Assmann, P Cullen, H Schulte Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study Circulation 105 2002 310 315
125. PM Ridker, JE Buring, NR Cook, N Rifai C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women Circulation 107 2003 391 397
126. MK Rutter, JB Meigs, LM Sullivan, RB D'Agostino Sr, PW Wilson C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study Circulation 110 2004 380 385
127. JB Meigs, K Williams, LM Sullivan Using metabolic syndrome traits for efficient detection of impaired glucose tolerance Diabetes Care 27 2004 1417 1426
128. ES Ford, WH Giles A comparison of the prevalence of the metabolic syndrome using two proposed definitions Diabetes Care 26 2003 575 581
129. PC van den Hoogen, EJ Feskens, NJ Nagelkerke, A Menotti, A Nissinen, D Kromhout The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group N Engl J Med 342 2000 1 8
130. J Liu, Y Hong, RB D'Agostino Sr Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study JAMA 291 2004 2591 2599
131. DB Carr, KM Utzschneider, RL Hull Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome Diabetes 53 2004 2087 2094
132. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults - The Evidence Report National Institutes of Health Obes Res 6 suppl 2 1998 51S 209S
133. WC Knowler, E Barrett-Connor, SE Fowler Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
134. P Zimmet, J Shaw, KG Alberti Preventing Type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view Diabet Med 20 2003 693 702
135. RE Brolin Bariatric surgery and long-term control of morbid obesity JAMA 288 2002 2793 2796
136. WJ Lee, MT Huang, W Wang, CM Lin, TC Chen, IR Lai Effects of obesity surgery on the metabolic syndrome Arch Surg 139 2004 1088 1092
137. PD Thompson, D Buchner, IL Pina Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity) Circulation 107 2003 3109 3116
138. J Tuomilehto, J Lindstrom, JG Eriksson Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance N Engl J Med 344 2001 1343 1350
139. SM Grundy, N Abate, M Chandalia Diet composition and the metabolic syndrome: what is the optimal fat intake? Am J Med 113 suppl 9B 2002 25S 29S
140. S Klein, NF Sheard, X Pi-Sunyer Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies. A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition Am J Clin Nutr 80 2004 257 263
141. CM Ballantyne, AG Olsson, TJ Cook, MF Mercuri, TR Pedersen, J Kjekshus Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S Circulation 104 2001 3046 3051
142. K Pyorala, CM Ballantyne, B Gumbiner Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care 27 2004 1735 1740
143. HB Rubins Triglycerides and coronary heart disease: implications of recent clinical trials J Cardiovasc Risk 7 2000 339 345
144. JT Chang, JA Staffa, M Parks, L Green Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy Pharmacoepidemiol Drug Saf 13 2004 417 426
145. EP van Puijenbroek, PW Du Buf-Vereijken, PF Spooren, JJ van Doormaal Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil J Intern Med 240 1996 403 404
146. AJ Bergman, G Murphy, J Burke Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans J Clin Pharmacol 44 2004 1054 1062
147. HE Bays, ME McGovern Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin Prev Cardiol 6 2003 179 188
148. SM Grundy, GL Vega, ME McGovern Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial Arch Intern Med 162 2002 1568 1576
149. AV Chobanian, GL Bakris, HR Black Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 2003 1206 1252
150. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes UKPDS 38. UK Prospective Diabetes Study Group BMJ 317 1998 703 713
151. S Julius, S Majahalme, P Palatini Antihypertensive treatment of patients with diabetes and hypertension Am J Hypertens 14 2001 310S 316S
152. CE Mogensen, ME Cooper Diabetic renal disease: from recent studies to improved clinical practice Diabet Med 21 2004 4 17
153. TA Buchanan, AH Xiang, RK Peters Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women Diabetes 51 2002 2796 2803
154. SM Grundy, JI Cleeman, CN Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
155. Standards of medical care in diabetes Diabetes Care 27 suppl 1 2004 S15 S35
156. V Fonseca Effect of thiazolidinediones on body weight in patients with diabetes mellitus Am J Med 115 suppl 8A 2003 42S 48S
157. SM Setter, JL Iltz, J Thams, RK Campbell Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy Clin Ther 25 2003 2991 3026
158. AJ Scheen Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system Drugs 64 2004 2537 2565
159. JA Colwell Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus Am J Cardiovasc Drugs 4 2004 87 106
160. TA Pearson, SN Blair, SR Daniels AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee Circulation 106 2002 388 391
161. TA Pearson, GA Mensah, RW Alexander Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 2003 499 511
162. FM van Dielen, WA Buurman, M Hadfoune, J Nijhuis, JW Greve Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery J Clin Endocrinol Metab 89 2004 4062 4068
163. I Jialal, D Stein, D Balis, SM Grundy, B Adams-Huet, S Devaraj Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels Circulation 103 2001 1933 1935
164. R Nesto C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones Diabet Med 21 2004 810 817